Human Vaccines And Immunotherapeutics impact factor, indexing, ranking (2024)


human

Aim and Scope

The Human Vaccines And Immunotherapeutics is a research journal that publishes research related to Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics. This journal is published by the Landes Bioscience. The ISSN of this journal is 21645515, 2164554X. Based on the Scopus data, the SCImago Journal Rank (SJR) of human vaccines and immunotherapeutics is 1.041.

Also, please check the following important details about human vaccines and immunotherapeutics: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

Human Vaccines And Immunotherapeutics Ranking

Journal Rank: 3952
SJR (SCImago Journal Rank): 1.041
Quartile: Q1
H-Index: 80

The SJR (SCImago Journal Rank) measures citations weighted by prestige. It is useful for comparing journals within the same field, and forms the basis of the subject category ranking. A journal SJR indicator is a numeric value representing the average number of weighted citations received during a selected year per document published in that journal during the previous three years, as indexed by Scopus. Higher SJR indicator values are meant to indicate greater journal prestige. SJR is developed by the Scimago Lab, originated from a research group at University of Granada. Q1 journals are cited more often and by more prestigious journals than those in the other quartiles.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.

CiteScore of an academic journal is a measure reflecting the yearly average number of citations to recent articles published in that journal. This journal evaluation metric was launched in December 2016 by Elsevier as an alternative to the generally used JCR impact factors (calculated by Clarivate). CiteScore is based on the citations recorded in the Scopus database rather than in JCR, and those citations are collected for articles published in the preceding four years instead of two or five.

Source Normalized Impact per Paper (SNIP) is calculated annually from Scopus data. It is a sophisticated metric that intrinsically accounts for field-specific differences in citation practices.



Important Metrics

Journal Title: Human Vaccines and Immunotherapeutics
Publisher: Landes Bioscience
ISSN: 21645515, 2164554X
Type: journal
Journal Scope: Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics
Country: United States
H-Index: 80
SJR: 1.041
Quartile: Medicine (miscellaneous) (Q1); Pharmacology (Q1); Immunology (Q2); Immunology and Allergy (Q2)

human vaccines and immunotherapeutics Indexing

The human vaccines and immunotherapeutics is indexed in:

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).


Human Vaccines And Immunotherapeutics Quartile

The latest Quartile of human vaccines and immunotherapeutics is Q1.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.



Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Human Vaccines And Immunotherapeutics?

If your research is related to Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics, then visit the official website of human vaccines and immunotherapeutics and send your manuscript.

Tips for publishing in Human Vaccines And Immunotherapeutics:

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Journal Publication Time

The publication time may vary depending on factors such as the complexity of the research and the current workload of the editorial team. Journals typically request reviewers to submit their reviews within 3-4 weeks. However, some journals lack mechanisms to enforce this deadline, making it difficult to predict the duration of the peer review process.

The review time also depends upon the quality of the research paper.


Final Summary

  • It is published by Landes Bioscience.
  • The journal is indexed in UGC CARE, Scopus, PubMed.
  • The (SJR) SCImago Journal Rank is 1.041.

Sources: human vaccines and immunotherapeutics







SIMILIAR JOURNALS


JOURNAL OF ANTIBIOTICS

ISSN: 0021-8820
Publisher: SPRINGERNATURE

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

ISSN: 0892-3973
Publisher: TAYLOR & FRANCIS LTD

REGULATORY TOXICOLOGY AND PHARMACOLOGY

ISSN: 0273-2300
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE

FOOD AND AGRICULTURAL IMMUNOLOGY

ISSN: 0954-0105
Publisher: TAYLOR & FRANCIS LTD

INFLAMMOPHARMACOLOGY

ISSN: 0925-4692
Publisher: SPRINGER BASEL AG

INNATE IMMUNITY

ISSN: 1753-4259
Publisher: SAGE PUBLICATIONS LTD

BIOMARKERS

ISSN: 1354-750X
Publisher: TAYLOR & FRANCIS LTD

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

ISSN: 1386-1964
Publisher: ELSEVIER

MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

ISSN: 1383-5718
Publisher: ELSEVIER

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

ISSN: 1383-5742
Publisher: ELSEVIER

TOP RESEARCH JOURNALS

Credit and Source: Scopus, Clarivate, UGC CARE.